Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Stock data | 2024 | Change |
---|---|---|
Price | $3.07 | N/A |
Market Cap | $24.30M | N/A |
Shares Outstanding | 7.91M | N/A |
Employees | 32.00 | N/A |